Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Fallopian Tube Cancer: early-phase trial registry
27 of 93 indexed Fallopian Tube Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #145 of 28,707 conditions by registered trial count.
93 US clinical trials · 27 currently recruiting · #145 of 28,707 conditions by registered trial count
Fallopian Tube Cancer: 93 US clinical trials tracked, 27 recruiting.
Fallopian Tube Cancer is the subject of 93 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 9 of these trials.
Enrollment posture brief
Registry condition fallopian-tube-cancer
OPEN 27 | RECR 29% | LATE 9 | EARLY 74 | RANK #145 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Nonalcoholic Steatohepatitis (29% recruiting · 31 trials)
Fallopian Tube Cancer lists 27 open slots (29% of 93 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Fallopian Tube Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Fallopian Tube Cancer is recruiting below its size-band peers.
27 of 93 indexed trials (29%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Fallopian Tube Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 9 of 93 trials (9.7%). 60 distinct sponsors appear on at least one study for this condition label.
-
Typical Fallopian Tube Cancer enrolment sits around 60 participants.
Median target enrolment is 60 among the 86 trials that report a genuine target (sentinel values excluded). 49 of those (57%) plan for fewer than 100 participants.
-
Fallopian Tube Cancer research is mostly interventional.
89 interventional and 4 observational studies make up this index (95.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
93 total, page 2 of 2
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
pharmaand
NCT01891344
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
AbbVie
NCT04209855
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Celgene
NCT01666444
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Linda R Duska
NCT01610206
Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
NCT01248962
Phase II ABT-888 With Cyclophosphamide
National Cancer Institute (NCI)
NCT01306032
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
ImmunoGen
NCT04296890
AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR
Amgen
NCT00770536
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
NCT03093155
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
Massachusetts General Hospital
NCT01652079
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
NCT00429793
Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors
Dana-Farber Cancer Institute
NCT00520013
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Morphotek
NCT00318370
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
City of Hope Medical Center
NCT00538031
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
Case Comprehensive Cancer Center
NCT01079832
Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Memorial Sloan Kettering Cancer Center
NCT00588237
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Benaroya Research Institute
NCT00343044
A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
AA Secord
NCT02728830
Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
NCT03332576
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
NCT00126542
Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Ronald Buckanovich
NCT03056833
Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors
Santa Maria Biotherapeutics
NCT02262455
Neoadjuvant Therapy for Ovarian Cancer
Jason D. Wright
NCT01146795
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
New Mexico Cancer Research Alliance
NCT01670799
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
National Cancer Institute (NCI)
NCT00993616
Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
Dana-Farber Cancer Institute
NCT00268918
Therapeutic Targeting of Stress Factors in Ovarian Cancer Patients
Washington University School of Medicine
NCT01308944
Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Gynecologic Oncology Group
NCT00003967
Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients
New Mexico Cancer Research Alliance
NCT02470299
Study of Safety & Biological Activity of IP IMNN-001 (also Known As GEN-1) with Neoadjuvant Chemo in Ovarian Cancer
Imunon
NCT02480374
Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Memorial Sloan Kettering Cancer Center
NCT02121990
Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Masonic Cancer Center, University of Minnesota
NCT01105650
Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Ludwig Institute for Cancer Research
NCT00803569
PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer
AA Secord
NCT00672295
Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers
Holy Name Medical Center
NCT03604653
Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian
Ritu Salani
NCT01219777
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
NCT00006041
Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
NCT00058435
Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract
NYU Langone Health
NCT00003334
Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Fred Hutchinson Cancer Center
NCT00217529
Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors
Beth Israel Deaconess Medical Center
NCT00004082
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer
Memorial Sloan Kettering Cancer Center
NCT00017017
Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers
Gynecologic Oncology Group
NCT00002538
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 39 |
| Phase 2 | 35 |
| Phase 3 | 9 |
Top Sponsors
Named interventions
Most-linked intervention names on Fallopian Tube Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Fallopian Tube Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Fallopian Tube Cancer page
93 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Fallopian Tube Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Fallopian Tube Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fallopian Tube Cancer condition card totals 93 registered trials; most-linked intervention Bevacizumab; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.